Douglas R. Cary

Douglas R. Cary

Auto-generated profile, based on publicly available information

Douglas R. Cary

Research, Takeda Pharmaceutical Co., Ltd., 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JFJun Fujimoto
Jun Fujimoto
OKOsamu Kurasawa
Osamu Kurasawa
TTTerufumi Takagi
Terufumi Takagi
XLXin Liu
Xin Liu
HBHiroshi Banno
Hiroshi Banno
RMRyo Mizojiri
Ryo Mizojiri

11 April 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MIMasahiro Ito
Masahiro Ito
TTToshio Tanaka
Toshio Tanaka
DCDouglas R. Cary
Douglas R. Cary
MIMisa Iwatani-Yoshihara
Misa Iwatani-Yoshihara
YKYusuke Kamada
Yusuke Kamada
YIYasuhiro Imaeda
Yasuhiro Imaeda

14 September 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
RMRyo Mizojiri
Ryo Mizojiri
DNDaisuke Nakata
Daisuke Nakata
YSYoshihiko Satoh
Yoshihiko Satoh
DMDaisuke Morishita
Daisuke Morishita
SSSachio Shibata
Sachio Shibata
YIYasuhiro Imaeda
Yasuhiro Imaeda
Starting from our previous eIF4A3-selective inhibitor 1a, a novel series of (piperazine-1-carbonyl)pyridin-2(1H)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds 1o and 1q showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds 1o and 1q showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition.

23 August 2021 in Organic Process Research & Development
Verified
Journal Article
Closed access
ANAkihiro Nagaya
Akihiro Nagaya
SMShota Murase
Shota Murase
YMYuji Mimori
Yuji Mimori
KWKazuya Wakui
Kazuya Wakui
MYMadoka Yoshino
Madoka Yoshino
NNNaoki Nishizawa
Naoki Nishizawa

23 June 2026 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KSKenichiro Shimokawa
Kenichiro Shimokawa
KOKoji Ono
Koji Ono
MAMoriteru Asano
Moriteru Asano
THTakaharu Hirayama
Takaharu Hirayama
HTHidekazu Tokuhara
Hidekazu Tokuhara
YAYasuyoshi Arikawa
Yasuyoshi Arikawa